Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial

Abstract

Adalimumab was safe and effective in 68% of refractory uveitis patients 10 weeks after study enrolment, and maintained in 39% after 1 year. Ongoing study is required to determine the place of adalimumab and other TNF blockers in the treatment of uveitis.

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

“…24 In another non-comparative open-label prospective study of 31 patients with refractory uveitis, 68% of patients were clinical responders at 10 weeks, with sustained response at 50 weeks seen in 39% of the patients. 25 A multicenter prospective study of 131 patients with a mean age of 27 years also demonstrated that adalimumab therapy significantly improved anterior chamber and vitreous inflammation with the ability to taper CS. 14 The French uveitis network recently published a multicenter observational study of 160 patients with refractory uveitis treated with anti-TNFα (infliximab and adalimumab) agents.…”

Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials

“…21 In another non-comparative open-label prospective study of 31 participants with refractory uveitis, 68% of participants were clinical responders at 10 weeks, and sustained response at 50 weeks was seen in 39% of the participants. 22 The French uveitis network recently published a multicenter study of 160 participants with refractory uveitis treated with anti-TNFα (infliximab and adalimumab) agents. The participants had an overall response rate of 93% at 12 months.…”

Corticosteroids and Anti-Complement Therapy in Retinal Diseases

“…Case series, observational studies, and open-label prospective clinical trials show that adalimumab can be efficacious for uveitis refractory to conventional immunosuppressive therapy in the context of scleritis, JIA-associated anterior uveitis, HLA-B27-associated anterior uveitis, tubulointerstitial nephritis and uveitis syndrome (TINU), ocular sarcoidosis, birdshot retinochoroidopathy, VKH, and idiopathic uveitis (Simonini et al 2014;Ragam et al 2014;Díaz-Llopis et al 2012;Restrepo and Molina 2010;Suhler et al 2013). An open-label study examining the efficacy of adalimumab for noninfectious uveitis refractory to at least one standard immunosuppressive medication showed a 68% response rate at 10 weeks and a 39% response rate at 50 weeks (Suhler et al 2013).…”

“…An open-label study examining the efficacy of adalimumab for noninfectious uveitis refractory to at least one standard immunosuppressive medication showed a 68% response rate at 10 weeks and a 39% response rate at 50 weeks (Suhler et al 2013). …”